New combo therapy aims to keep High-Risk nasopharyngeal cancer at bay

NCT ID NCT06093061

Recruiting now Disease control Sponsor: National Cancer Centre, Singapore Source: ClinicalTrials.gov ↗

First seen Apr 15, 2026 · Last updated May 23, 2026 · Updated 5 times

Summary

This study tests a one-year maintenance treatment combining tislelizumab (an immunotherapy) and low-dose capecitabine (a chemotherapy) in 53 adults with high-risk nasopharyngeal cancer. Participants have a specific marker (detectable EBV DNA) after initial chemotherapy, indicating a higher chance of cancer returning. The goal is to see if this combination improves the chance of staying cancer-free for two years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Cancer Centre Singapore
RECRUITING

Singapore, 168583, Singapore
Tan Tock Seng Hospital
RECRUITING

Singapore, 308433, Singapore

Conditions

Explore the condition pages connected to this study.

NASOPHARYNGEAL CARCINOMA